{"organizations": [], "uuid": "d62a18a80dc50869f11cab1ee6295265f7acd7b7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180222.html", "section_title": "Archive News &amp; Video for Thursday, 22 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-novo-nordisk-says-successfully-com/brief-novo-nordisk-says-successfully-completes-first-trial-for-oral-semaglutide-idUSASM000JLY", "country": "US", "domain_rank": 408, "title": "BRIEF-Novo Nordisk Says Successfully Completes First Trial For Oral Semaglutide", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.558, "site_type": "news", "published": "2018-02-22T17:51:00.000+02:00", "replies_count": 0, "uuid": "d62a18a80dc50869f11cab1ee6295265f7acd7b7"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-novo-nordisk-says-successfully-com/brief-novo-nordisk-says-successfully-completes-first-trial-for-oral-semaglutide-idUSASM000JLY", "ord_in_thread": 0, "title": "BRIEF-Novo Nordisk Says Successfully Completes First Trial For Oral Semaglutide", "locations": [], "entities": {"persons": [{"name": "jacob gronholt-pedersen", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "novo nordisk", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 22 (Reuters) - NOVO NORDISK SAYS:\n* SUCCESSFULLY COMPLETES THE FIRST PHASE 3A TRIAL, PIONEER 1, WITH ORAL SEMAGLUTIDE\n* ‍TRIAL ACHIEVED ITS PRIMARY OBJECTIVE ACCORDING TO PRIMARY STATISTICAL PRINCIPLE BY DEMONSTRATING SIGNIFICANT AND SUPERIOR IMPROVEMENTS IN HBA (LONG-TERM BLOOD SUGAR) FOR ALL THREE DOSES OF ORAL SEMAGLUTIDE COMPARED TO PLACEBO​\n* 14 MG DOSE OF ORAL SEMAGLUTIDE DEMONSTRATED SIGNIFICANT AND SUPERIOR WEIGHT LOSS VERSUS PLACEBO, WEIGHT LOSS WAS OBSERVED FOR 7 MG AND 3 MG DOSES BUT DID NOT REACH STATISTICAL SIGNIFICANCE​\n* ‍WE ARE VERY ENCOURAGED BY RESULTS OF PIONEER 1 TRIAL, WHICH CONFIRM UNPRECEDENTED ORAL EFFICACY OF SEMAGLUTIDE THAT WAS REPORTED IN PHASE 2 CLINICAL TRIAL IN TYPE 2 DIABETES​\n* ‍WE LOOK FORWARD TO PROVIDING DATA FROM REMAINING NINE PIONEER TRIALS THROUGHOUT THIS YEAR AND AN EXPECTED REGULATORY SUBMISSION IN 2019​ SOURCE TEXT FOR EIKON: FURTHER COMPANY COVERAGE: (Reporting by Jacob Gronholt-Pedersen)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-22T17:51:00.000+02:00", "crawled": "2018-02-23T15:34:11.079+02:00", "highlightTitle": ""}